Avacta Group Plc Early progress towards therapeutic Affimers

Hardman & Co ReportAvacta Group Plc (LON:AVCT) is a life science company providing high quality and highly specific tools to the biopharmaceutical industry to help in the diagnosis and treatment of humans and animals. The group’s Affimer technology is a revolutionary alternative to the established antibody technology which dominates the drug industry despite its limitations. During 2015 Avacta focused all activities on the commercialisation of Affimers initially via a bespoke service and an on-line catalogue, with a longer-term view to develop its own bio-therapeutics for out-licensing. There is a clear mismatch between the EV of ca.£50m and the long-term potential of Affimers.
► Interims: Publication of interim results is more about updating the market about progress in the identification and development of therapeutic Affimers than the actual numbers themselves. The most important figure is that, following the £21.0m (net) cash injection in 2015, £25.0m remains on deposit.

► Immuno-oncology: Avacta has delivered on a number of Affimer candidates in 1H’16 that bind to and inhibit activity of the PD-L1 checkpoint protein, proving the company’s ability to find Affimers with activity against specific drug targets. Some candidates have entered pre-clinical testing to identify the best leads.

► Blood clotting disorders: Avacta has commenced a two-year pre-clinical study to examine the effects of Affimer candidates on clot formation and prevention. Once in-vitro & in-vivo data are available, the best candidates will be considered for clinical studies as potential drugs for clotting disorders or anti-thrombotics.

► Risks: Although Affimers have significant advantages over traditional antibody technology, the customer base might take time to realise these advantages and adapt to a new disruptive technology. Avacta is minimising this risk by initially focusing on areas where antibodies are unavailable or perform poorly.

► Investment summary: The enterprise value of Avacta Group Plc does not reflect the value that big pharma is prepared to pay for new technologies and assets. The median up-front paid is US$17m and US$40m for pre-clinical and Phase I assets respectively. These figures were exemplified superbly by the deals that Molecular Partners secured for its comparable DARPin technology.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Hardman & Co

More articles like this

Avacta Group Plc

Avacta plc notice regarding publication error

Regarding a recent aggregated news article published earlier today, which has since been taken down, this was an error on the DirectorsTalk part linking to old news. This was nothing to do with Avacta Plc. The

Avacta Group Plc

Avacta inks radiopharma deal with POINT Biopharma

UK-based Avacta Group (AIM: AVCT) has entered into a license agreement with Canadian firm POINT Biopharma to provide access to Avacta’s pre|CISION technology for the development of tumor-activated radiopharmaceuticals.  The radiopharmaceutical market is expected to grow

Avacta Group Plc

Avacta signs new cancer therapy deal

Avacta Group, the developer of innovative cancer therapies, has entered into a license agreement with Point Biopharma to provide access to Avacta’s technology for the development of tumour-activated radiopharmaceuticals. Radiopharmaceutical therapy is now seen as a

Avacta Group Plc

Research looks to improve wastewater testing for COVID-19

Accurately identifying changes in community COVID-19 infections through wastewater surveillance is moving closer to reality. A new study, published in Environmental Science & Technology, identifies a method that not only detects the virus in wastewater samples but also

Avacta Group Plc

Hopes for clinical trial on humans of tumour targeting drug

Hopes for clinical trial of tumour targeting drug by Avacta. The company has filed an application for phase one testing, for its pre|CISION prodrug AVA6000. If approved, it will be tested on patients with metastatic solid tumours. The

Avacta Group Plc

BioSpace global roundup

U.K.-based Avacta Group announced significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical

Avacta Group Plc

Talks could trigger COVID test rollout

Cambridge biotech Avacta Group is in discussions with commercial partners to establish a route to market for a CE marked BAMS COVID-19 test that can be deployed in hospitals in the UK and Europe. It is